Crizotinib

Active Ingredient: Crizotinib
Form: Capsule
Brand Name: Xalkori
Generic Name: Crizona
Generic Manufacturer: Ziska Pharmaceuticals

Indications:
Xalkori is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in patients whose tumors are ALK-positive or ROS1-positive as confirmed by an approved test.

Dosage and Administration:
The recommended dose is 250 mg orally twice daily. For patients with severe renal impairment, the dose may be adjusted to 250 mg once daily. If a dose is missed or vomiting occurs, follow your physician’s instructions.

Common Side Effects:
Visual disturbances, nausea, diarrhea, vomiting, edema, constipation, elevated liver enzymes, fatigue, decreased appetite, upper respiratory infections, dizziness, and neuropathy.

Storage:
Store below 30°C in a cool, dry place away from light and moisture. Keep out of reach of children.

Frequently Asked Questions

Q: What is the relationship between Xalkori and Crizotinib?
A: Xalkori is the original brand name registered by the manufacturer. Crizotinib is its active ingredient.

Q: Is the Xalkori sold by Mediva Rx the original brand-name drug?
A: No. Mediva Rx provides a high-quality generic version manufactured by one of Bangladesh’s top 10 pharmaceutical companies. It has the same active ingredient and therapeutic effect as the original, and is tested and approved by the Directorate General of Drug Administration (DGDA).

Q: Is the manufacturer of this generic version reliable?
A: Yes. We partner with Ziska Pharmaceuticals, a leading pharmaceutical company in Bangladesh with in-house R&D, production, and quality control facilities. The company is internationally certified for pharmaceutical manufacturing standards. You can purchase with confidence.

Disclaimer:
This information is for reference only. Please follow your physician’s instructions and consult the official medication guide and the latest clinical research when making treatment decisions.

Drug Instructions (Package Insert):
Download Link